Yong Yu sold $16k of GNLX
SVP, Clinical Development at GENELUX Corp. 4,192 shares at an average of $3.82, traded Aug 21, 2025, filed Dec 11, 2025.
Score components
- +15RoleOfficer
- 0Trade size$16k at market
- 0Share of holdings soldSold 2.8% of holdings
- +15Cluster4 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001493152-25-027338, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 21, 2025 | SOpen-market sale Common Stock | -3,219 | $3.36 | $11k | 146,817 | Dec 11, 2025 |
| Nov 17, 2025 | SOpen-market sale Common Stock | -973 | $5.37 | $5,224 | 145,844 | Dec 11, 2025 |
Related signals
Other insiders at GENELUX Corp and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 35Weak | GENELUX Corp | Joseph Cappello Chief Technical Officer | $28k 10,257 shares | -3% | |
| 35Weak | GENELUX Corp | Yong Yu Chief Scientific Officer | $27k 9,683 shares | -4% | |
| 49Moderate | GENELUX Corp | Thomas Zindrick President and CEO | $92k 34,463 shares | -3% | |
| 30Weak | GENELUX Corp | Joseph Cappello Chief Technical Officer | $14k 3,706 shares | -2% | |
| 48Moderate | GENELUX Corp | Thomas Zindrick President and CEO | $66k 17,182 shares | -3% | |
| 30Weak | GENELUX Corp | Ralph Smalling Head of Regulatory | $8,740 2,332 shares | -3% | |
| 2Weak | GENELUX Corp | John Thomas director | $50k 10,000 shares | -2% | |
| 30Weak | GENELUX Corp | Joseph Cappello VP, Pharmaceutical Development | $14k 4,737 shares | -8% | |
| 30Weak | GENELUX Corp | Ralph Smalling Head of Regulatory | $3,676 1,259 shares | -3% | |
| 35Weak | GENELUX Corp | Yong Yu VP, Clinical Trial Operations | $16k 5,579 shares | -10% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.